Display Settings:

Format

Send to:

Choose Destination
    Psychopharmacol Bull. 1995;31(4):785-8.

    Open-label trial of venlafaxine in adults with attention deficit disorder.

    Source

    New York University Medical Center, NY, USA.

    Abstract

    Antidepressants or stimulants are commonly used to treat attention deficit disorder (ADD). We report the results of an open-label trial of the recently marketed antidepressant venlafaxine in 16 adult patients with ADD. Patients were treated with venlafaxine (25 to 225 mg/day) for 8 weeks. Four patients discontinued treatment within the first week because of sedation, agitation, or nausea. In the remaining 12 patients, venlafaxine treatment decreased ADD ratings by almost half.

    PMID:
    8851654
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk